RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RHB-107 (upamostat)3 has been accepted for inclusion in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. Government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa. The Company also announced that the Phase 2 study, predominantly funde

Related Keywords

China ,United Kingdom ,Macao ,Macau General ,Macau ,United States ,Taiwan ,Hong Kong ,Adi Frish ,Redhill Biopharma ,Nasdaq ,Germany Heidelberg Pharmaceuticals ,Program Executive Office For Chemical ,Exchange Commission ,Company Expanded Access Program ,Department Of The Navy ,Corporate Business Development ,National Institutes Of Health Radiation ,Department Of The Army ,Redhill Biopharma Ltd ,Nuclear Defense ,Nuclear Countermeasures Program For Acute Radiation Syndrome ,Consortium For Enhanced Sepsis Outcomes ,Company Annual Report On Form ,Department Of Defense ,Military Medicine ,Gilead Raday ,Chief Operating Officer ,National Institutes ,Health Radiation ,Nuclear Countermeasures Program ,Acute Radiation Syndrome ,Heidelberg Pharmaceuticals ,Joint Program Executive Office ,Joint Force ,Enhanced Sepsis Outcomes ,Hill Biopharma ,Private Securities Litigation Reform Act ,Expanded Access Program ,Annual Report ,Nhjf ,Iacceso ,Peo Cbrnd ,Oint Program Executive Office For Chemical ,Biological ,Hb 107 ,Henrym Jackson Foundation ,Redhill ,Investigational Products ,Phase 2 Study ,